These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2544 related items for PubMed ID: 7781141

  • 1. Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
    Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N, Grandi M.
    Cancer Chemother Pharmacol; 1995; 36(3):217-22. PubMed ID: 7781141
    [Abstract] [Full Text] [Related]

  • 2. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
    Sola F, Farao M, Ciomei M, Pastori A, Mongelli N, Grandi M.
    Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
    [Abstract] [Full Text] [Related]

  • 3. New sulfonated distamycin A derivatives with bFGF complexing activity.
    Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, Mongelli N.
    Biochem Pharmacol; 1994 Jan 20; 47(2):295-302. PubMed ID: 7508230
    [Abstract] [Full Text] [Related]

  • 4. In vivo activity of novel sulphonic derivatives of distamycin A.
    Sola F, Biasoli G, Pesenti E, Farao M, Della Torre P, Mongelli N, Grandi M.
    EXS; 1992 Jan 20; 61():459-62. PubMed ID: 1377572
    [Abstract] [Full Text] [Related]

  • 5. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
    Pezzoni G, Grandi M, Biasoli G, Capolongo L, Ballinari D, Giuliani FC, Barbieri B, Pastori A, Pesenti E, Mongelli N.
    Br J Cancer; 1991 Dec 20; 64(6):1047-50. PubMed ID: 1764367
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
    Zamai M, Hariharan C, Pines D, Safran M, Yayon A, Caiolfa VR, Cohen-Luria R, Pines E, Parola AH.
    Biophys J; 2002 May 20; 82(5):2652-64. PubMed ID: 11964252
    [Abstract] [Full Text] [Related]

  • 10. Tissue uptake, distribution, and potency of the photoactivatable dye chloroaluminum sulfonated phthalocyanine in mice bearing transplantable tumors.
    Chan WS, Marshall JF, Lam GY, Hart IR.
    Cancer Res; 1988 Jun 01; 48(11):3040-4. PubMed ID: 3284641
    [Abstract] [Full Text] [Related]

  • 11. Selective DNA interaction of the novel distamycin derivative FCE 24517.
    Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F, D'Incalci M.
    Cancer Res; 1991 Jan 01; 51(1):199-204. PubMed ID: 1859575
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of novel sulphonic derivatives of distamycin A.
    Mariani M, Paio A, Ciomei M, Pastori W, Franzetti C, Melegaro G, Grandi M, Mongelli N.
    EXS; 1992 Jan 01; 61():455-8. PubMed ID: 1377571
    [Abstract] [Full Text] [Related]

  • 13. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y, Song S, Yang F, Au JL, Wientjes MG.
    J Pharmacol Exp Ther; 2001 Nov 01; 299(2):426-33. PubMed ID: 11602651
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J.
    Cancer Res; 1987 Jul 15; 47(14):3707-11. PubMed ID: 3594435
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
    Filippeschi S, Colombo T, Bassani D, De Francesco L, Arioli P, D'Incalci M, Bartosek I, Guaitani A.
    Anticancer Res; 1988 Jul 15; 8(6):1351-4. PubMed ID: 3064716
    [Abstract] [Full Text] [Related]

  • 18. Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate).
    Zamai M, Caiolfa VR, Pines D, Pines E, Parola AH.
    Biophys J; 1998 Aug 15; 75(2):672-82. PubMed ID: 9675169
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor.
    Manetti F, Cappello V, Botta M, Corelli F, Mongelli N, Biasoli G, Borgia AL, Ciomei M.
    Bioorg Med Chem; 1998 Jul 15; 6(7):947-58. PubMed ID: 9730230
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA.
    Cancer Res; 1987 Nov 15; 47(22):5846-52. PubMed ID: 3664486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 128.